A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach

<b>Background/Objective:</b> Sacubitril/Valsartan are a combination drug approved for heart failure treatment, known to enhance natriuretic peptide activity and inhibit the renin–angiotensin–aldosterone system (RAAS). While its clinical efficacy is well-established, its broader impact on...

Full description

Bibliographic Details
Published in:	Pharmaceuticals
Main Authors:	Randh AlAhmari, Hana M. A. Fakhoury, Reem AlMalki, Hatouf H. Sukkarieh, Lina Dahabiyeh, Tawfiq Arafat, Anas M. Abdel Rahman
Format:	Article
Language:	English
Published:	MDPI AG 2025-08-01
Subjects:	Sacubitril/Valsartan metabolomics LC-QToF HRMS pyrimidine metabolism pharmacokinetics uridine triphosphate
Online Access:	https://www.mdpi.com/1424-8247/18/9/1264

Similar Items

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
by: Marina Nikolic, et al.
Published: (2022-11-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Chronic Diarrhoea associated with Sacubitril-Valsartan use in an Elderly Female - The Benefits of Unprescribing
by: Sankha Shubhra Chakrabarti, et al.
Published: (2020-01-01)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Data on effect of Sacubitril/valsartan on cardiac Remodelling in diabetic Cardiomyopathy rats
by: Jiao Ai, et al.
Published: (2021-04-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
by: José-Manuel Rubio-Campal, et al.
Published: (2025-06-01)

Retrospective analysis of influences of sacubitril/valsartan in patients with diabetes with poorly controlled blood pressure in Japan
by: Shun Ito, et al.
Published: (2025-10-01)

Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry
by: José Manuel Rubio Campal, et al.
Published: (2021-05-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020
by: Nancy Herrera-Leaño, et al.
Published: (2024-01-01)

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)

The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure
by: Alireza Arzhangzadeh, et al.
Published: (2025-05-01)

Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
by: Bin Wang, et al.
Published: (2022-03-01)

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
by: Shuangcui Wang, et al.
Published: (2023-05-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia
by: Alshammari A, et al.
Published: (2024-01-01)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
by: Cong Zhao, et al.
Published: (2022-11-01)

Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
by: Maja Nikolic, et al.
Published: (2022-06-01)

Long-Term Effects of Sacubitril/Valsartan After Chemotherapy for Breast Cancer in Patients With Chronic heart Failure
by: S. G. Kanorskiy, et al.
Published: (2024-03-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Effectiveness of Sacubitril/Valsartan in Preventing Heart Failure in STEMI Post-Percutaneous Coronary Intervention
by: Nobian Andre, et al.
Published: (2023-12-01)

Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update
by: Antoine Garnier-Crussard
Published: (2024-08-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
by: Reza Mohebi, et al.
Published: (2023-10-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
by: Einar Sjaastad Nordén, et al.
Published: (2025-04-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Repurposing Artrestan (Sacubitril/Valsartan), unveiling its anti-inflammatory and fibrinolytic properties in ulcerative colitis in rats
by: Khatereh Kharazmi, et al.
Published: (2025-10-01)

Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
by: Narainrit Karuna, et al.
Published: (2025-05-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
by: Juan Jiang, et al.
Published: (2023-03-01)